公开(公告)号：US12195453B2

公开(公告)日：2025-01-14

申请号：US17930352

申请日：2022-09-07

Applicant: Merck Patent GmbH ,  Vertex Pharmaceuticals Incorporated

Inventor： Henry Yu ,  Michael Clark ,  Guy Bemis ,  Michael Boyd ,  Kishan Chandupatla ,  Philip Collier ,  Hongbo Deng ,  Huijun Dong ,  Warren Dorsch ,  Russell R. Hoover ,  Mac Arthur Johnson, Jr. ,  Shashank Kulkarni ,  Marina Penney ,  Steven Ronkin ,  Darin Takemoto ,  Qing Tang ,  Nathan D. Waal ,  Tiansheng Wang ,  David J. Lauffer ,  Pan Li

IPC: C07D413/04 ,  A61K31/506 ,  A61K31/553 ,  A61P35/00 ,  C07D401/14 ,  C07D403/04 ,  C07D413/14 ,  C07D417/14 ,  C07D491/107 ,  C07D491/113

Abstract: The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US20190322673A1

公开(公告)日：2019-10-24

申请号：US16391407

申请日：2019-04-23

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： David J. Lauffer ,  Guy Bemis ,  Michael Boyd ,  David Deininger ,  Hongbo Deng ,  Warren Dorsch ,  Wenxin Gu ,  Russell R. Hoover ,  Mac Arthur Johnson, JR. ,  Mark Willem Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Marina Penney ,  Darin Takemoto ,  Nathan D. Waal ,  Tiansheng Weng

IPC: C07D487/04 ,  C07D491/20 ,  C07D487/14 ,  C07D471/04 ,  C07D471/14 ,  C07D498/04 ,  C07D519/00

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US11572364B2

公开(公告)日：2023-02-07

申请号：US17188132

申请日：2021-03-01

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： David Lauffer ,  Guy Bemis ,  Michael Boyd ,  David Deininger ,  Hongbo Deng ,  Warren Dorsch ,  Wenxin Gu ,  Russell R. Hoover ,  Mac Arthur Johnson, Jr. ,  Mark Willem Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Marina Penney ,  Darin Takemoto ,  Nathan D. Waal ,  Tiansheng Wang ,  Pan Li

IPC: C07D471/04 ,  C07D487/04 ,  C07D491/20 ,  C07D487/14 ,  C07D519/00 ,  C07D471/14 ,  C07D498/04

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US11440907B1

公开(公告)日：2022-09-13

申请号：US17004109

申请日：2020-08-27

Applicant: Merck Patent GmbH ,  Vertex Pharmaceuticals Incorporated

Inventor： Henry Yu ,  Michael Clark ,  Guy Bemis ,  Michael Boyd ,  Kishan Chandupatla ,  Philip Collier ,  Hongbo Deng ,  Huijun Dong ,  Warren Dorsch ,  Russell R. Hoover ,  Mac Arthur Johnson, Jr. ,  Shashank Kukarni ,  Marina Penney ,  Steven Ronkin ,  Darin Takemoto ,  Qing Tang ,  Nathan D. Waal ,  Tiansheng Wang ,  David J. Lauffer ,  Pan Li

IPC: A61K31/506 ,  A61K31/553 ,  A61P35/00 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D491/107 ,  C07D417/14 ,  C07D403/04 ,  C07D491/113

Abstract: The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US20160168147A1

公开(公告)日：2016-06-16

申请号：US15049812

申请日：2016-02-22

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Christopher Lee Brummel ,  Francois Maltais ,  David D. Deininger ,  Brian Ledford ,  Warren Dorsch

IPC: C07D471/04 ,  C07D239/42 ,  C07F5/02

CPC classification number: C07D471/04 ,  C07B59/002 ,  C07D239/42 ,  C07D239/95 ,  C07F5/025

Abstract: The present invention relates to deuterated compounds that are useful for inhibiting Janus kinases and processes and intermediates useful for preparing such compounds.

Abstract translation: 本发明涉及可用于抑制Janus激酶的氘代化合物和用于制备这些化合物的方法和中间体。

公开(公告)号：US11059826B2

公开(公告)日：2021-07-13

申请号：US16391407

申请日：2019-04-23

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： David J. Lauffer ,  Guy Bemis ,  Michael Boyd ,  David Deininger ,  Hongbo Deng ,  Warren Dorsch ,  Wenxin Gu ,  Russell R. Hoover ,  Mac Arthur Johnson, Jr. ,  Mark Willem Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Marina Penney ,  Darin Takemoto ,  Nathan D. Waal ,  Tiansheng Wang ,  Pan Li

IPC: C07D471/04 ,  C07D487/04 ,  C07D491/20 ,  C07D487/14 ,  C07D519/00 ,  C07D471/14 ,  C07D498/04

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US10815225B2

公开(公告)日：2020-10-27

申请号：US16391419

申请日：2019-04-23

Applicant: Merck Patent GmbH ,  Vertex Pharmaceuticals Incorporated

Inventor： Henry Yu ,  Michael Clark ,  Guy Bemis ,  Michael Boyd ,  Kishan Chandupatla ,  Philip Collier ,  Hongbo Deng ,  Huijun Dong ,  Warren Dorsch ,  Russell R. Hoover ,  Mac Arthur Johnson, Jr. ,  Shashank Kukarni ,  Marina Penney ,  Steven Ronkin ,  Darin Takemoto ,  Qing Tang ,  Nathan D. Waal ,  Tiansheng Wang ,  David J. Lauffer ,  Pan Li

IPC: A61P35/00 ,  A61K31/506 ,  A61K31/553 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D491/107 ,  C07D417/14 ,  C07D491/113 ,  C07D403/04

Abstract: The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US20190322658A1

公开(公告)日：2019-10-24

申请号：US16391419

申请日：2019-04-23

Applicant: Merck Patent GmbH ,  Vertex Pharmaceuticals Incorporated

Inventor： Henry Yu ,  Michael Clark ,  Guy Bemis ,  Michael Boyd ,  Kishan Chandupatla ,  Philip Collier ,  Hongbo Deng ,  Huijun Dong ,  Warren Dorsch ,  Russell R. Hoover ,  Mac Arthur Johnson, JR. ,  Shashank Kukarni ,  Marina Penney ,  Steven Ronkin ,  Darin Takemoto ,  Qing Tang ,  Nathan D. Waal ,  Tiansheng Wang

IPC: C07D413/14 ,  A61P35/00 ,  C07D417/14 ,  C07D403/04 ,  C07D401/14 ,  C07D413/04 ,  C07D491/113 ,  C07D491/107

Abstract: The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US20230150993A1

公开(公告)日：2023-05-18

申请号：US17930352

申请日：2022-09-07

Applicant: Merck Patent GmbH ,  Vertex Pharmaceuticals Incorporated

Inventor： Henry YU ,  Michael Clark ,  Guy Bemis ,  Micheal Boyd ,  Kishan Chandupatla ,  Philip Collier ,  Hongbo Deng ,  Huijun Dong ,  Warren Dorsch ,  Russell R. Hoover ,  Mac Arthur Johnson, JR. ,  Shashank Kulkarni ,  Marina Penney ,  Steven Ronkin ,  Darin Takemoto ,  Qing Tang ,  Nathan D. Waal ,  Tiansheng Wang ,  David J. Lauffer ,  Pan Li

IPC: C07D413/14 ,  A61P35/00 ,  C07D417/14 ,  C07D491/107 ,  C07D401/14 ,  C07D413/04 ,  C07D491/113 ,  C07D403/04

CPC classification number: C07D413/14 ,  A61P35/00 ,  C07D417/14 ,  C07D491/107 ,  C07D401/14 ,  C07D413/04 ,  C07D491/113 ,  C07D403/04

Abstract: The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US20130190289A1

公开(公告)日：2013-07-25

申请号：US13723668

申请日：2012-12-21

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Jeremy Green ,  Dean M. Wilson ,  Laval Chan Chun Kong ,  Sanjoy Kumar Das ,  Carl Poisson ,  John J. Court ,  Qing Tang ,  Pan Li ,  Philip N. Collier ,  Nathan Waal ,  David J. Lauffer ,  Warren Dorsch

IPC: C07D413/12 ,  C07D409/12 ,  C07D333/38

CPC classification number: C07D413/12 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4535 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D333/38 ,  C07D409/12 ,  C07D409/14 ,  C07D491/08 ,  C07D491/10

Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.